Vyndaqel, the brand name for the medicine known as tafamidis, is approved to treat transthyretin amyloid cardiomyopathy. Pfizer said the disease affects about 100,000 people in the U.S., the majority of whom are undiagnosed. About 2,000 to 5,000 patients are currently diagnosed with the heart disease worldwide.
Pfizer told Reuters it is confident that insurers will reimburse the $225,000 price.
Outside the U.S. the drug sells for about $100,000 a year.
Analysts expect sales of the drug to exceed $1 billion by 2024.
Read the full report here.
More articles on pharmacy:
Insys execs guilty of opioid racketeering scheme
Walgreens shaking up C-suite
Generic drugmakers could thrive in a recession, Moody’s says
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
